adenine has been researched along with plx4032 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iida, S | 1 |
| Bagby, SM; Burstyn-Cohen, T; Carrico, J; DeRyckere, D; Earp, HS; Eckhardt, SG; Frye, SV; Graham, DK; Kami, R; Minson, KA; Robinson, WA; Sinik, L; Tentler, JJ; Wang, X | 1 |
| He, QY; Hong, P; Hu, HF; Huang, XH; Li, B; Xu, WW; Yan, X; Yang, J; Ye, F; Zhang, QH | 1 |
| Chekalin, E; Chen, B; Doseff, AI; Gallo, KA; Misek, SA; Neubig, RR; Newbury, PA; Paithankar, S | 1 |
1 review(s) available for adenine and plx4032
| Article | Year |
|---|---|
Overview: A New Era of Cancer Genomics in Lymphoid Malignancies.
Topics: Adenine; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Genome, Human; Genomics; High-Throughput Nucleotide Sequencing; Humans; Indoles; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Molecular Targeted Therapy; Mutation; Piperidines; Precision Medicine; Pyrazoles; Pyrimidines; Sulfonamides; Vemurafenib | 2015 |
3 other study(ies) available for adenine and plx4032
| Article | Year |
|---|---|
Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Topics: Adenine; Animals; Azetidines; c-Mer Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; GTP Phosphohydrolases; Humans; Melanoma; Membrane Proteins; Mice; Mutation; Phosphorylation; Piperazines; Piperidines; Proto-Oncogene Proteins B-raf; Signal Transduction; Vemurafenib | 2019 |
Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction.
Topics: Adenine; Antineoplastic Agents; CDC2 Protein Kinase; Cell Line, Tumor; Colonic Neoplasms; Humans; Organophosphonates; Protein Binding; Proteins; Reverse Transcriptase Inhibitors; Vemurafenib | 2019 |
Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Melanoma; Piperidines; Proto-Oncogene Proteins B-raf; Vemurafenib; YAP-Signaling Proteins | 2022 |